NCT02426229View on ClinicalTrials.gov

Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

June 30, 2018

Study Completion Date

June 21, 2018

Conditions
SclerodermaInterstitial Lung Disease
Interventions
DRUG

dabigatran etexilate

dabigatran etexilate 75mg orally twice a day for 6 months

Trial Locations (1)

29425

Medical University of South Carolina, Charleston

All Listed Sponsors
collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

lead

Medical University of South Carolina

OTHER

NCT02426229 - Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma | Biotech Hunter | Biotech Hunter